Protara Therapeutics (TARA) Long-Term Deferred Tax (2013 - 2023)
Protara Therapeutics (TARA) posted quarterly Long-Term Deferred Tax of $54.3 million for Q4 2023, up 3574.22% year-over-year from $1.5 million in Q4 2022, and up 3574.22% quarter-over-quarter from $1.5 million in Q4 2022.
Protara Therapeutics (TARA) Long-Term Deferred Tax (2013 - 2023) Analysis & Trends
Protara Therapeutics (TARA) has reported Long-Term Deferred Tax for 7 consecutive years, with $54.3 million the latest figure, recorded in Q4 2023.
- In Q4 2023, Long-Term Deferred Tax rose 3574.22% year-over-year to $54.3 million; the TTM figure through Dec 2023 stood at $54.3 million (up 3574.22% YoY), while the FY2023 annual figure was $54.3 million, up 3574.22% from the prior year.
- Long-Term Deferred Tax rose to $54.3 million in Q4 2023 per TARA's latest filing, from $1.5 million in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $54.3 million in Q4 2023 and bottomed at $322000.0 in Q4 2020.
- Historically, Long-Term Deferred Tax has averaged $16.7 million across 5 years, with a median of $4.2 million in 2019.
- Annual changes were most pronounced in 2021 — Long-Term Deferred Tax soared 7151.55% — and 2022, when it tumbled 93.67%.
- Protara Therapeutics' Long-Term Deferred Tax stood at $4.2 million in 2019, then tumbled by 92.29% to $322000.0 in 2020, then jumped by 7151.55% to $23.3 million in 2021, then sank by 93.67% to $1.5 million in 2022, then jumped by 3574.22% to $54.3 million in 2023.
- Business Quant data shows TARA's Long-Term Deferred Tax at $54.3 million in Q4 2023, $1.5 million in Q4 2022, and $23.3 million in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Protara Therapeutics | 234.56 Mn | 234.56 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 54.31 Mn |
| Dec 31, 2022 | 1.48 Mn |
| Dec 31, 2021 | 23.35 Mn |
| Dec 31, 2020 | 322,000.00 |
| Dec 31, 2019 | 4.18 Mn |
| Jun 30, 2017 | 600,000.00 |
| Mar 31, 2017 | 600,000.00 |
| Dec 31, 2013 | 267,000.00 |